DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

Market Cap	142.78B +5.8%
Revenue (ttm)	242.69B -2.6%
Net Income	50.27B +2,369.7%
EPS	1,791.00 +2,288.0%
Shares Out	27.04M
PE Ratio	2.95
Forward PE	n/a
Dividend	120.00 (2.20%)
Ex-Dividend Date	Dec 29, 2025

Volume	127,664
Average Volume	161,313
Open	5,250.00
Previous Close	5,290.00
Day's Range	5,030.00 - 5,260.00
52-Week Range	4,745.00 - 6,390.00
Beta	0.47
RSI	42.07
Earnings Date	Apr 2, 2026

About DongKoo Bio & Pharma

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antip...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 404
• Stock Exchange: KOSDAQ
• Ticker Symbol: 006620

Financial Performance

In 2025, DongKoo Bio & Pharma's revenue was 242.69 billion, a decrease of -2.64% compared to the previous year's 249.27 billion. Earnings were 50.27 billion, an increase of 2369.74%.